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Abstract 
Background: Transient production of gamma-retroviruses, including self-inactivating (SIN) retroviruses, is a common 
method for rapidly generating virus capable of gene delivery. Stable (continuous) production of virus is preferable to 
transient production for clinical and biotechnology purposes, however, because it allows for significant quantities of a 
uniform virus to be generated over a prolonged period of time, thus allowing for longitudinal functional studies and 
quality analysis. Unfortunately, stable production of SIN retroviruses is difficult to achieve.
Results: We describe a novel method to rapidly and cost-effectively create packaging cells capable of continuously 
producing self-inactivating gamma-retroviruses. We imbedded the SIN proviral construct into a minimal piggyBac 
transposon vector and then integrated the hybrid vector into packaging cells that already stably expressed the viral 
gag-pro-pol and envelope genes. Cells that stably produced self-inactivating gamma-retroviruses could be identified 
(and purified) as early as 3 weeks after initial transfection; these cells produced virus for at least 9 weeks without a 
decline in titer.
Conclusions: This viral-minimal piggyBac hybrid vector allowed for the rapid generation and purification of packag-
ing cells capable of stably producing self-inactivated gamma-retroviruses. This method can be applied to the large-
scale production of viruses for use in research, biotechnology, and potentially, clinical trials.
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Background
Gamma-retroviral vectors were first used in gene ther-
apy clinical trials in 1990 [1–4] and remain an important 
method for stably introducing genes into cells. While 
viral production can be accomplished more quickly by 
the short-term (transient) transfer of plasmids [5, 6], con-
tinuous stable production of virus is highly desirable for 
clinical and biotechnology purposes [7]. Stable produc-
tion allows for the large-scale generation of a uniform 
virus, facilitating its full characterization. It also reduces 
the labor involved in repeatedly transfecting packaging 
cells to obtain virus [1].
The use of wild type vectors, in which the viral core is 
integrated into the packaging cell during the initial infec-
tion [7], is an easy method for generating stable gamma-
retroviral producing cells. Unfortunately, wild type 
vectors are more prone to insertional oncogenesis and 
cell immortalization than self-inactivated (SIN) vectors 
[8–13] reducing enthusiasm for their use. In addition to 
a better safety profile, SIN vectors also eliminate inter-
nal promoter interference which allows for improved 
transgene expression [14]. This makes them a better 
choice than wild type vectors for generating stable virus-
producing cells. The absence of an enhancer in both long 
terminal repeats (LTR) of SIN retroviruses significantly 
attenuates virus production in packaging cell lines after 
they are integrated, however [15]. Therefore, while creat-
ing stable SIN retroviral-producing cells is possible, it is 
tedious and time-consuming [16].
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Recently we developed a modified piggyBac transpo-
son delivery system in which the transposase gene and 
most of both terminal domains were relocated from the 
delivery cassette into the helper (non-integrating) part of 
the same plasmid without a significant loss of transposi-
tion efficiency [17]. Similar to classical piggyBac vectors, 
these truncated (minimal) transposon vectors can deliver 
a large amount of transgenic DNA, yet incorporate sig-
nificantly less helper DNA (fewer than 100 base pairs) 
than classical piggyBac vectors or retroviruses. In addi-
tion, this minimal piggyBac system has the advantage of 
requiring only a single-plasmid for delivery. This manu-
script describes the practical application of this minimal 
piggyBac vector system for the large-scale manufacture 
of clinical-grade, self-inactivating gamma-retroviral vec-
tors. We used this minimal piggyBac delivery system to 
efficiently integrate SIN retroviral sequences and genes 
necessary for cell selection such as antibiotic resistance 
or fluorescent markers into packaging cells. By incorpo-
rating a selection marker within the integrated transpo-
son, but outside the gamma-retroviral sequence, we were 
able to rapidly select only the cells that had integrated 
the entire provirus and thus, able to stably produce SIN 
virus.
Methods
Phoenix (HEK293 backbone) amphotropic packaging 
cells were purchased from Orbigen, Inc. (San Diego, CA). 
They were used for transfection and infection experi-
ments as virus producer and target cells. Cells were cul-
tured in DMEM, 10  % FBS, 2  mmol  l-Glutamine and 
routinely passaged after reaching 80  % confluency. All 
cells were grown in humidified incubators at 37 °C in 5 % 
CO2 and harvested by 0.05  % trypsin/0.53  mM EDTA 
digestion and counted with Coulter Z1 (Coulter Elec-
tronics). Counts were made in triplicate.
RNAi-Ready pSIREN-RetroQ-ZsGreen Vector was 
purchased from ClonTech (Mountain View, CA). It is 
a self-inactivating (SIN) retroviral expression vector 
due to a truncation in the 3′ LTR enhancer/promoter 
region (U3). The hybrid 5′ LTR consists of the cytomeg-
alovirus (CMV) type I enhancer and the mouse sar-
coma virus (MSV) promoter. A BglII-BamHI deletion of 
the U6 promoter and ligation of the vectors ends with 
a linker to recover EcoRI site generated plasmid B. We 
then replaced the truncated U3 fragment of the 3′LTR 
in plasmid B (XhoI-SacI restriction sites fragment) with 
a full-length U3 part of the 3′LTR from the retroviral 
vector pBMN-GFP (BsrGI-SacI fragment) (purchased 
from Orbigen, San Diego, CA) to generate plasmid A. 
This transformed the SIN 3′LTR in retroviral plasmid B 
into a wild type 3′LTR, while preserving all other viral 
sequences including the hybrid CMV/MSV/5′LTR, pack-
aging sequence (Ψ) and the CMV driven ZsGreen iden-
tical to those in plasmid B. An SspI-EcoRI deletion in 
plasmid B generated control plasmid D.
The vector 166 (described in Ref. [17]) was used as the 
base for constructing the hybrid minimal piggyBac/retro-
viral plasmid C. Vector 166 was modified by replacing the 
minSV40 promoter for piggyBac transposase expression 
and the CMV promoter driving turboRFP expression 
for PGK and EF1α promoters respectively (Fig. 1c). The 
Fig. 1 Detailed schematic of plasmids. All four plasmids contained a ZsGreen reporter gene driven by a cytomegalovirus (CMV) promoter. Func-
tional retroviral sequences required for virus production (indicated by the line designated RV) are present in plasmids A, B, and C. Control plasmid 
D lacked the 5′ LTR and the packaging sequence (Ψ) and therefore was not able to generate virus, but expressed ZsGreen. In hybrid plasmid C the 
retroviral sequence was imbedded into the minimal piggyBac vector (line designated as minPB). The reporter gene, RFP (turboRFP—Red Fluorescent 
Protein) is driven by the EF1α promoter. PiggyBac transposase and truncated piggyBac terminal domains are required for minimal piggyBac integra-
tion, but these sequences do not integrate into target chromatin. Arrows indicate the orientation of the operons. Prokaryotic origin of replication 
and ampicillin resistance gene are not shown. (Vectors are aligned for easier comparison, but distances are not drawn to scale). LTR full-length 
wild type gamma-retroviral long terminal repeat, CMV/MSV/5′LTR hybrid 5′ LTR consists of the CMV type I enhancer, MSV the mouse sarcoma virus 
promoter linked to the truncated part of the retroviral long terminal repeat, 3′LTR(SIN) self-inactivated retroviral long terminal repeat, TRmin minimal 
piggyBac terminal repeat, pA SV40 polyadenylation signal, BPase piggyBac transposase gene driven by the PGK promoter, TD(trunc.) truncated pig-
gyBac terminal domain
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entire SIN retroviral construct from plasmid B (SspI-DraI 
restriction sites fragment) was inserted into a BamHI site 
in the modified plasmid 166 in the same orientation as 
the turboRFP and piggyBac transposase genes to make 
plasmid C.
Amphotropic packaging cells were transfected with 
these test plasmids using FuGENE HD reagent follow-
ing the manufacturer’s instructions for virus produc-
tion (each expressing ZsGreen with excitation/emission 
of 496/506  nm; plasmid C also expressing turboRFP 
with excitation/emission of 553/574  nm). Forty-eight 
hours or 21  days after transfection, the cells were har-
vested by 0.05  % trypsin/0.53  mM EDTA digestion, 
washed, and analyzed/sorted (Figs.  2a, 3a) using a BD 
Biosciences FACSAria cell sorter in the University 
of South Alabama Flow Cytometry Core. The sorted 
cells were re-seeded for virus production experiments 
for an additional 9  weeks. Viral-conditioned media 
was refreshed and then collected 12  h later; it was 
then filtered, supplemented with hexadimethrine bro-
mide (polybrene) to a final concentration of 4  µg/ml 
and applied directly to target cells. The cell density of 
virus-producing and target cells was the same for all 
reported transfection/infection experiments. To titrate 
virus, we applied 10  ml of increasingly diluted con-
ditioned medium to 1.5  ×  106 target cells and deter-
mined infection efficiency using flow cytometry. The 
viral titer was calculated within the linear range based 
on the percentage of ZsGreen-positive cells over several 
virus dilutions. For other experiments, we applied 10 ml 
of medium to 4 ×  106 target cells and calculated viral 
titer within the linear (i.e. non-saturating) range of viral 
infectivity.
Data are expressed as mean  ±  SE. Changes in per-
centage of ZsGreen, turboRFP or ZsGreen/turboRFP-
expressing cells, and virus titer were compared using 
ANOVA combined with Fisher post hoc analysis, with a 
P value <0.05 considered significant.
Fig. 2 a Percentage of ZsGreen, turboRFP or ZsGreen/turboRFP positive packaging cells 48 h after transfection (i.e. transiently positive) with tested 
plasmids. RV wild type retroviral vector A, RV(SIN) SIN retroviral vector B, RV(SIN)minPB SIN retroviral/minimal piggyBac hybrid vector C, Control nega-
tive control vector D. b, c The viral titers (IU infectious units/ml) in the medium of two sequential passages of retrovirus originated from transiently 
transfected plasmids. Viral conditioned medium was collected from virus-producing cells 48 h after transfection with plasmids A–D and then 
applied to other packaging cells (1st infection cycle, b). Only cells expressing the viral marker (ZsGreen) after the 1st infection cycle were purified 
and their conditioned medium tested for retroviral SIN function using new target cells (2nd infection cycle, c). (Data are expressed as mean ± SE; 
n = 4 experiments; *P < 0.05)
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Results and discussion
We used minimal piggyBac transposon vectors to effi-
ciently deliver a SIN gamma-retroviral core into the pack-
aging cell genome to allow for stable virus production. To 
begin, we constructed three gamma-retroviral plasmids 
each containing the fluorescent marker, ZsGreen, under 
control of the CMV promoter (Fig. 1): plasmid A was a 
wild type retrovirus with an intact 3′ LTR; plasmid B was 
a SIN retrovirus (with a truncated 3′LTR); and plasmid C 
was a hybrid minimal piggyBac/SIN-retroviral vector that 
included the entire SIN proviral construct (identical to 
Plasmid B) and also contained turboRFP as a transposon 
reporter. Plasmid D lacked both the 5′ LTR and the retro-
viral packaging sequence and thus was unable to generate 
virus; it was used as a negative control. Cell density and 
medium volumes in all experiments were kept similar to 
allow us to calculate variations in viral titer for each of 
the vectors.
The initial transfection efficiency of all three retroviral 
(A–C) and control (D) plasmids in Phoenix amphotropic 
packaging cells (Orbigen, San Diego, CA), as determined 
by the percentage of ZsGreen positive cells (or ZsGreen/
turboRFP positive cells for plasmid C) 48  h after trans-
fection, was similar (approximately 84 %; Fig. 2a); the fact 
that plasmid C was 2kB larger than the other plasmids 
had no effect on transfection efficiency. Conditioned 
medium was collected from these transfected cells at 
3  days and then applied to other amphotropic packag-
ing cells to determine their viral titer (1st infection cycle). 
Conditioned medium from cells that had integrated virus 
after the 1st infection cycle (as determined by ZsGreen 
positivity after infection) was collected and applied to 
other amphotropic packaging cells to determine their 
viral titer during a 2nd infection cycle. This experimental 
design allowed us to determine if virus infectivity could 
be maintained through both infection cycles.
Fig. 3 a Percentage of ZsGreen, turboRFP or ZsGreen/turboRFP positive packaging cells 21 days after transfection (i.e. stably positive) with tested 
plasmids. RV wild type retroviral vector A, RV(SIN) SIN retroviral vector B, RV(SIN)minPB SIN retroviral/minimal piggyBac hybrid vector C, Control nega-
tive control vector D. b, c The viral titers (IU infectious units/ml) in the medium of two sequential passages of retrovirus originated from stably inte-
grated constructs. Twenty-one days after transfection with the three retroviral plasmids, only virus-producing cells expressing ZsGreen (populations 
A, B and C’) or both ZsGreen and turboRFP (population C) were purified and their conditioned medium applied to other packaging cells for infec-
tion (1st infection cycle, b). Only cells expressing the viral marker (ZsGreen) after the 1st infection cycle were purified and their conditioned medium 
tested for retroviral SIN function using new target cells (2nd infection cycle, c). (Data are expressed as mean ± SE; n = 4 experiments; *P < 0.05)
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Conditioned medium harvested 3  days after transfec-
tion with the three retroviral plasmids (A–C) demon-
strated an equivalent viral titer (Fig. 2b); cells transfected 
with plasmid D did not make virus and therefore were 
not analyzed further. As expected, only conditioned 
medium collected from cells infected with the wild type 
virus (virus A) was able to infect cells during a 2nd infec-
tion cycle with the same efficiency as that of the parental 
cells (Fig.  2c, A). We did observe a low-level produc-
tion of retrovirus in cells infected with the SIN virus 
in the 2nd infection cycle, however (Fig.  2c, B, C). This 
was most likely due to reactivation of the 5′ LTR(SIN) 
promoter in some cells as previously suggested by other 
investigators [18].
Our goal was to create packaging cells capable of sta-
bly generating SIN gamma retroviruses, however. This 
required the integration of the SIN provirus into the 
packaging cell genome without losing its ability to pro-
duce infectious viral particles. To determine whether 
an integrated SIN provirus could stably produce virus, 
we examined viral titers of conditioned media 3  weeks 
after the initial transfection. We chose this time-point 
because we have previously demonstrated [17] that 
HEK293 cells either integrated or eliminated the mini-
mal piggyBac constructs within 3 weeks of transfection. 
Therefore, transfected cells that continued to express 
ZsGreen at 21 days were assumed to have incorporated 
the viral construct. 10.1 % of cells transfected with plas-
mid A (wild type) and 2.3 % transfected with plasmid B 
(SIN) were ZsGreen positive at 21 days. The higher per-
centage of ZsGreen cells in wild type-infected cells was 
likely due to the continued infection of cells by the inte-
grated wild type provirus which was capable of making 
active virus. In contrast, the integrated SIN provirus was 
not capable of generating infectious particles, so there 
was minimal cross infection in culture leading to fewer 
ZsGreen-positive cells. Cells transfected with plasmid C 
generated two different populations of cells at 21  days: 
population C’ (ZsGreen-only positive indicating cells that 
had integrated only the retrovirus during the 21  days, 
likely through cross infection) and population C (both 
ZsGreen and turboRFP positive indicating cells in which 
the entire transposon, with the imbedded retrovirus, had 
been integrated into the cell). Cells expressing these fluo-
rescent markers 21 days after transfection (Fig. 3a) were 
purified by flow cytometry and studied further. This gave 
a total of four sub-populations of cells (A, B, C, and C’).
These four populations of cells were used for two cycles 
of virus propagation/collection/infection/analysis experi-
ments as described previously in this paper. Only cells 
that had integrated the wild type virus (A) or those that 
had integrated the hybrid minimal piggyBac/SIN gamma-
retroviral construct (C) were able to produce sufficient 
levels of virus in this 1st round of infection (Fig. 3b). As 
expected, only viral vector A was able to produce virus 
capable of infecting target cells in the 2nd amplifica-
tion/collection/infection cycle (Fig.  3c). The inability of 
double-positive cells (C) to produce virus that remained 
infectious beyond a single passage indicated that the SIN 
function of the integrated retrovirus was retained. Both 
the wild type (A) and the SIN (C) retroviral producing 
cells were able to maintain virus production, without any 
appreciable drop in titer, for at least 63 days after purifi-
cation by flow cytometry (Fig. 4a), sufficient time to not 
only fully characterize the virus, but also to produce it on 
a scale suitable for most biotechnology and clinical appli-
cations. Table 1 summarizes the use of the tested vectors 
in transient and stable virus production formats.
We used separate reporter markers for the viral and the 
non-viral parts of the transposon (hybrid) vector. This 
significantly improved our ability to distinguish between 
cells that had incorporated the entire hybrid minimal pig-
gyBac/SIN gamma-retroviral construct (and were thus 
capable of generating infectious SIN gamma-retrovirus) 
from those that had only integrated the retrovirus (and 
thus unable to generate infectious SIN gamma retrovi-
rus). Integration of transposons, like integration of ret-
roviruses, is a random event, however. Therefore, even 
within the population of cells that had integrated the 
entire piggyBac/SIN gamma-retroviral construct, the site 
of integration was not likely to be the same in each cell. 
Over time this could lead to variable virus production 
if certain cells overgrew the population. To determine 
whether this occurred in these cells, we randomly gener-
ated six individual clones that expressed both fluorescent 
markers (ZsGreen and TurboRFP) 21 days after transfec-
tion and expanded them in culture. Eighty-four days after 
transfection, all of the six clones produced virus with a 
similar titer to that from a non-clonal cell population also 
cultured for total of 84 days (after transfection) (Fig. 4b). 
This result suggests that in mixed (non-clonal) infected 
populations of packaging cells, the majority of cells make 
virus at comparable rates; thus, cloning of infected cells 
is not required, reducing the cost and time of generating 
these packaging cells.
In these experiments we used the same cells for both 
virus production and targeting which allowed us to com-
pare the first (transient) and second (stable) cycles of 
virus infectivity. However, in packaging cells that already 
stably express viral GAG-POL and envelope proteins, re-
infection occurs with a lower efficiency [7]. This likely 
explains the lower viral titer in these cells compared to 
HEK293 cells without these viral proteins. Yet, despite 
this inhibition, the viral titers obtained are compara-
ble to those used in the manufacturing of clinical-grade 
SIN gamma-retroviral vectors [6, 19]. The infectivity of 
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gamma-retroviruses depends on the susceptibility of 
specific target cells to infection and also can be affected 
by other enhancing technologies [20, 21]. The methods 
described in this manuscript technique are relevant only 
to gamma-retroviral vectors since the continuous expres-
sion of the lentiviral GAG-PRO is known to be toxic to 
packaging cells [22].
Minimal piggyBac vectors [17] can incorporate DNA 
sequences up to (at least) 15 Kb into cells (unpublished 
data) allowing the stable delivery of large retroviral 
sequences. Using this vector to deliver the SIN retroviral 
construct increased the efficiency of proviral DNA incor-
poration into virus producing cells more than 30-times 
compared with the use of non-transposon stable plasmid 
delivery systems [from 0.3 ± 0.1 (ZsGreen positive cells, 
plasmid D) to 9.1 ± 1.1 % (ZsGreen/RFP double positive 
cells, plasmid C); Fig. 3a]. Usual piggyBac vectors can also 
be used for gamma-retroviral delivery [23]. Two impor-
tant advantages of using a minimal rather than a classical 
piggyBac vector, however, are that the minimal vector is 
a single plasmid system which allows for more efficient 
delivery and that transposons integrated into cells remain 
non-removable even in the presence of transposase. Thus, 
minimal piggyBac vector can be used repeatedly for mul-
tiple integration events without the risk of losing previ-
ously integrated fragments. No additional components, 
such as helper plasmids, proteins or mRNAs (commonly 
used with traditional transposon systems) are needed. 
The proposed system provides a continuously-producing, 
highly-consistent cell system that can be used to generate 
SIN retroviral vectors that meet the standard for current 
Good Manufacturing Practices [1, 2, 24].
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Fig. 4 a Viral titer (IU infectious units/ml) in conditioned medium from infected, but non-clonal populations of cultured packaging cells over time. 
Viral-producing cells that contained either the stably incorporated wild type retroviral construct (expressing ZsGreen, population A) or the hybrid-
SIN vector (expressing both ZsGreen and turboRFP, population C) were obtained 21 days after transfection and cultured for an additional 35 and 
63 days (56 and 84 days after transfection). Conditioned media was collected at the indicated time points and the viral titer compared to the titer 
at 21 days. A cells that integrated wild type retrovirus by infection; C cells that integrated the SIN retrovirus-piggyBac hybrid by transposition. b Viral 
titer (IU infectious units/ml) in conditioned medium from six randomly generated clones of packaging cells 84 days after transfection with plasmid 
C. Viral-producing cells that stably incorporated the minimal piggyBac/SIN retroviral construct (as determined by cells that expressed both ZsGreen 
and turboRFP (population C) 21 days after transfection) were purified and propagated in culture for an additional 63 days. The viral titer in the condi-
tioned media from each clone at this time was determined as previously described for the non-clonal population of cells. (Data are expressed as 
mean ± SE; n = 4 experiments)
Table 1 Wild type (WT) and  self-inactivated (SIN) virus 
production by the used vectors
Vector Production format
Transient Stable
A: RV WT WT
B: RV(SIN) SIN –
C: RV(SIN)minPB SIN SIN
D: Control – –
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